SynthesisEye (London, England)2026
Growth hormone therapy and ocular biometry in paediatric growth hormone deficiency: a systematic review and meta-analysis.
Synthesis in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are essential regulators of somatic growth and may also influence ocular development, yet their effects on specific ocular biometric parameters remain insufficiently defined. This systematic review and meta-analysis investigated the impact of GH deficiency and GH replacement therapy on ocular outcomes in paediatric populations. A comprehensive search of PubMed, Embase, Web of Science, and Cochrane databases up to January 2025 identified randomised controlled trials, cohort studies, and case-control studies comparing ocular parameters between GH-treated individuals and healthy controls. Eight observational studies met inclusion criteria. Pooled analyses showed that GH therapy was significantly associated with increased intraocular pressure (mean difference [MD] 1.95 mmHg), central corneal thickness (MD 22.62 µm), and spherical equivalent (MD 0.45 dioptres), accompanied by reduced axial length (MD -0.94 mm), all reaching statistical significance. No meaningful differences were observed in refraction. Moderate to high heterogeneity was noted across some outcomes but improved substantially in leave-one-out sensitivity analyses, supporting the robustness of the findings. Overall, the results indicate that GH therapy produces measurable alterations in ocular parameters among children with GH deficiency, reinforcing the role of the GH-IGF-1 axis in ocular development and intraocular physiology. These findings underscore the importance of routine ophthalmologic monitoring in GH-treated patients and highlight the need for well-designed prospective studies to clarify long-term visual consequences and the clinical relevance of these biometric changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.